TW201442722A - 肽於治療心血管適應症之用途 - Google Patents

肽於治療心血管適應症之用途 Download PDF

Info

Publication number
TW201442722A
TW201442722A TW103102790A TW103102790A TW201442722A TW 201442722 A TW201442722 A TW 201442722A TW 103102790 A TW103102790 A TW 103102790A TW 103102790 A TW103102790 A TW 103102790A TW 201442722 A TW201442722 A TW 201442722A
Authority
TW
Taiwan
Prior art keywords
hours
natriuretic peptide
patient
peptide
urodilator
Prior art date
Application number
TW103102790A
Other languages
English (en)
Chinese (zh)
Inventor
Johannes Holzmeister
Original Assignee
Cardiorentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ltd filed Critical Cardiorentis Ltd
Publication of TW201442722A publication Critical patent/TW201442722A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
TW103102790A 2013-01-25 2014-01-24 肽於治療心血管適應症之用途 TW201442722A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25

Publications (1)

Publication Number Publication Date
TW201442722A true TW201442722A (zh) 2014-11-16

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103102790A TW201442722A (zh) 2013-01-25 2014-01-24 肽於治療心血管適應症之用途

Country Status (19)

Country Link
US (2) US20140213520A1 (cg-RX-API-DMAC10.html)
EP (1) EP2948165A2 (cg-RX-API-DMAC10.html)
JP (1) JP2016505065A (cg-RX-API-DMAC10.html)
KR (1) KR20150108903A (cg-RX-API-DMAC10.html)
CN (1) CN105025918A (cg-RX-API-DMAC10.html)
AP (1) AP2015008624A0 (cg-RX-API-DMAC10.html)
AU (1) AU2014208851B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015017432A2 (cg-RX-API-DMAC10.html)
CA (1) CA2898571A1 (cg-RX-API-DMAC10.html)
DO (1) DOP2015000175A (cg-RX-API-DMAC10.html)
EA (1) EA201500765A1 (cg-RX-API-DMAC10.html)
IL (1) IL239909A0 (cg-RX-API-DMAC10.html)
MX (1) MX2015009606A (cg-RX-API-DMAC10.html)
NZ (1) NZ710246A (cg-RX-API-DMAC10.html)
PH (1) PH12015501559A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201505492XA (cg-RX-API-DMAC10.html)
TN (1) TN2015000315A1 (cg-RX-API-DMAC10.html)
TW (1) TW201442722A (cg-RX-API-DMAC10.html)
WO (1) WO2014115033A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1995033769A1 (de) 1994-06-02 1995-12-14 Boehringer Mannheim Gmbh Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP2004510743A (ja) * 2000-10-04 2004-04-08 モレキュラー　メディシン　リサーチ　インスティチュート レラキシンのアゴニストまたはアンタゴニストの投与によるアポトーシスを調節する方法
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7732406B2 (en) * 2005-04-07 2010-06-08 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
WO2009034134A2 (en) * 2007-09-11 2009-03-19 Pharis Biotec Gmbh Use of natriuretic peptides for treating angioedema syndromes
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
AU2009246112B2 (en) * 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Ｓｉｒｓ患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
PH12012500562A1 (en) * 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
EP2547356A1 (en) * 2010-03-15 2013-01-23 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
EP2605797A2 (en) * 2010-08-20 2013-06-26 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
EA201500765A1 (ru) 2015-12-30
WO2014115033A3 (en) 2015-02-26
AP2015008624A0 (en) 2015-07-31
DOP2015000175A (es) 2015-11-15
CN105025918A (zh) 2015-11-04
MX2015009606A (es) 2016-04-26
TN2015000315A1 (en) 2017-01-03
US20140213519A1 (en) 2014-07-31
SG11201505492XA (en) 2015-08-28
CA2898571A1 (en) 2014-07-31
PH12015501559A1 (en) 2015-09-21
US20140213520A1 (en) 2014-07-31
JP2016505065A (ja) 2016-02-18
NZ710246A (en) 2016-11-25
KR20150108903A (ko) 2015-09-30
AU2014208851B2 (en) 2016-12-22
WO2014115033A2 (en) 2014-07-31
BR112015017432A2 (pt) 2017-07-11
AU2014208851A1 (en) 2015-08-06
IL239909A0 (en) 2015-08-31
EP2948165A2 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
EP2510942B1 (en) Use of natriuretic peptide for treating heart failure
EP2288373B1 (en) Relaxin for use in treating of dyspnea associated with acute heart failure
RU2768283C2 (ru) Семаглутид при сердечно-сосудистых состояниях
JP2011520917A (ja) 慢性心不全の治療方法
AU2014208851B2 (en) A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications
WO2022029499A1 (en) Methods of treating refractory ascites
HK1151229B (en) Relaxin for use in treating of dyspnea associated with acute heart failure
AU2013201629A1 (en) Treating dyspnea associated with acute heart failure with relaxin